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Abstract
Melatonin is a promising cardioprotective agent. Its increase during the night 
is associated with healthy cardiovascular function. On the other hand, reduced 
levels of melatonin are related to diseases. Aging and chronodisruptors reduce 
melatonin levels. Pharmacological supplementation reduces the deleterious effects 
of cardiovascular risk factors and improves the myocardial response to ischemia/
reperfusion injury and other proarrhythmic conditions. The protective mecha-
nisms of melatonin involve its antioxidant properties as well as receptor-mediated 
actions. Signaling pathways include membrane responses, cytoplasmic modula-
tion of kinases, nuclear receptor interactions, and improvement of mitochondrial 
functions. This chapter focuses on the electrophysiological and the antiarrhythmic 
properties of melatonin. The acute and chronic protective mechanisms of melatonin 
will be analyzed with an emphasis on transmembrane potentials and intercel-
lular communication. An outstanding antifibrillatory effect makes melatonin a 
novel antiarrhythmic agent worthy of further exploration in the path to clinical 
applications.
Keywords: melatonin, arrhythmias, ventricular fibrillation, action potential, 
connexin 43, melatonin receptors
1. Introduction
“Nothing to do to save his life…” says the Beatles song “Good morning, good 
morning.” Ironically, cardiovascular mortality and life-threatening arrhythmias 
show a circadian increase in the mornings, and chronoprotective agents are still 
missing [1, 2]. This chapter highlights the importance of melatonin as a potential 
life-saving agent for the darkest nights (of antiarrhythmics drugs) and a brightest 
tomorrow.
The cardioprotective properties of melatonin are remarkable. Most of the 
preclinical and clinical studies support the protective actions and the safety profile 
of this indolamine [3, 4]. In this chapter, we briefly introduce the multitarget and 
versatile properties of melatonin and general concepts of electrophysiology to 
appreciate its potential as a promising antiarrhythmic agent. The second and third 
sections of the chapters focus on acute and chronic melatonin’s antiarrhythmic 
effects.
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1.1 Melatonin properties relevant to heart rhythms
Endogenous and pharmacological increases of melatonin concentrations protect 
the cardiovascular system [3–11]. However, the relationships between the cardio-
vascular and circadian systems are highly complex and should not be interpreted in 
reductionist ways [5, 12–14]. Furthermore, our understanding of the pleiotropy of 
melatonin, a highly preserved molecule of protection, is continuously expanding 
[3–7, 10, 15–24]. Therefore, we will focus on melatonin effects on heart rhythms. 
Additional information regarding melatonin cardiovascular effects can be found 
elsewhere and include direct actions in the heart, blood vessels, kidney, and other 
regulatory mechanisms at the nervous, immune, and endocrine systems [11, 25, 
26]. Only the electrophysiological information will be extracted from its protective 
actions against risk factors like hypertension, metabolic syndrome, obesity, inflam-
mation, and pathologies like ischemia/reperfusion injury, infarction, drug-induced 
cardiotoxicity, diabetic cardiomyopathy, and heart failure [8, 11, 21, 27].
Melatonin is amphipathic and pleiotropic. Melatonin can act on several targets 
at cell membranes and at intracellular levels in almost any cell [28, 29]. For this 
electrophysiological analysis, we present the following division of melatonin 
mechanisms of action:
a. Antioxidant
b. Receptor activation
c. Improvement of mitochondrial functions
d. Ion channel modulation
1.1.1 Melatonin as an antioxidant
Melatonin protects against oxidants by several mechanisms. In fact, it has been 
suggested that one of the main functions of melatonin in all living organisms is 
to protect them from oxidative stress [30, 31]. Melatonin has a well-characterized 
and extensively documented antioxidant capacity [31–37]. Melatonin is a powerful 
antioxidant, with a potency of up to 10 times greater than vitamin E [38].
There are oxidants of different chemical nature. They can be free radicals or 
non-radical reactive species [39, 40]. Free radicals—molecules with an unpaired 
electron—are unstable, highly reactive, and often trigger chain reactions, which 
propagate nearby molecular modifications. The most studied oxidants are the 
reactive oxygen species (ROS), reactive nitrogen species (RNS), and reactive sulfur 
species. Under physiological conditions, ROS/RNS act as second intracellular 
messengers modulating signal transduction pathways [40, 41]. A delicate cellular 
balance between the production and the removal of free radicals maintains low/
moderate concentrations. Oxidative stress occurs when oxidants increase above 
healthy levels and represent a severe risk to the molecular integrity of lipids, pro-
teins, and DNA [39, 40]. Therefore, neutralization of reactive species by scavenger 
molecules like melatonin is a chemical way of counteracting oxidative stress.
The main agent involved in oxidative damage is superoxide anion, but hydrogen 
peroxide, hydroxyl radical, nitric oxide (NO), peroxynitrite, and nitroxyl also 
participate in oxidative stress. The mitochondria are the main source of oxidizing 
species during oxidative phosphorylation. Oxidants are also the product of the 
activation of non-mitochondrial enzyme systems such as NADPH oxidase, xanthine 
oxidase, and nitric oxide synthase [40–42].
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Cells have antioxidants that prevent damage. An antioxidant is any substance 
that significantly delays or prevents oxidation of lipids, proteins, or DNA [40]. 
Lipids are often used as target molecules because they are more reactive to oxidants 
than proteins or DNA. Nonenzymatic antioxidants include reduced glutathione 
(GSH), vitamins, and melatonin among others. Melatonin is five times more 
effective than GSH as scavenger of the highly toxic hydroxyl radical [34]. The main 
antioxidant enzymes are superoxide dismutase (SOD), catalase, thioredoxin, and 
glutathione peroxidase [40–44].
Melatonin efficiently prevents oxidative stress. The aromatic indole ring of 
melatonin reduces and repairs electrophilic radicals acting as generous electron 
donor. One molecule of melatonin can neutralize up to 10 toxic reagents, including 
ROS, RNS, and other free radicals [7, 39, 45–47]. In addition, several metabolites 
formed when melatonin neutralizes harmful reagents are also antioxidants suggest-
ing that a cascade of reactions increases the efficacy of melatonin [28, 35, 47–49]. 
Being a highly lipophilic and hydrophilic compound, melatonin crosses all mor-
phological barriers and acts not only in each cell but also within each subcellular 
compartment. Additionally, melatonin increases the efficacy of vitamin E, vitamin 
C, and GSH [33, 50]. Therefore, the elimination of free radicals can be carried out 
by intracellular interactions independent of any receptor [36, 45, 51].
Melatonin stimulates antioxidant enzymes by acting on membrane, cytoplas-
mic, and nuclear receptors [39, 43, 52]. Low melatonin concentrations increase the 
expression or activity of SOD, catalase, and glutathione peroxidase [43, 53].
Ion channels and many other proteins respond to oxidative stress [54–58]. Amino 
acid residues are the targets of ROS/RNS. Sulfur atoms like cysteine and methionine, 
hydroxyl groups from tyrosine, or aromatic rings of histidine, phenylalanine, and 
tryptophan are vulnerable to reactive species. Those that contain more cysteines are 
more sensitive to changes because thiol groups (–SH), which exist as thiolates (–S) 
at physiological pH, tend to react more quickly with ROS/RNS [59]. Many of these 
proteins are involved in important biological reactions such as oxidative phosphory-
lation, metabolic regulation, and signal transduction [60, 61]. Oxidative stress can 
increase late sodium currents through direct Na+ channel modification [62, 63] 
and result in a prolonged action potential duration and arrhythmogenic triggers 
known as early-after depolarizations (EAD) [64]. Several reviews describe the redox 
regulation of calcium channel in cardiac myocytes including the ryanodine receptor 
calcium, the IP3 receptor, and voltage-dependent L-type calcium channel [65–69]. 
ROS and RNS affect the L-type Ca2+ channel Cav1.2 by regulation of cysteine 
residues. However, calcium channel regulation by redox is controversial with reports 
of increase and decrease of channel functions [66]. Voltage-gated potassium (Kv) 
channel, mainly responsible for myocardial repolarization, is sensitive to oxidative 
stress [58, 70–72]. Sulfenic acid modification at a conserved cysteine residue of 
Kv1.5 under prolonged oxidative stress can induce arrhythmia [58, 72].
1.1.2 Melatonin receptors
Melatonin has receptors in the cellular membranes, in the cytoplasm, and in the 
nucleus. Melatonin membrane receptors express in several regions of the nervous 
system and in almost all the organs including the heart, arteries, kidneys, liver, gas-
trointestinal tract, prostate gland, uterus, skin, and eyes [73]. Melatonin activates 
two subtypes of G-protein-coupled receptors in the plasma membrane, named MT1 
and MT2, according to the official IUPHAR nomenclature (previously called Mel1a 
and Mel1b) [74]. Both receptors have high affinity to melatonin (Kd ~ 0.1 pM). In 
2019, Stauch and Johansson reported the crystal structures of the human MT1 and 
MT2 and set a solid base concerning ligand recognition for both receptors [75, 76].
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Melatonin membrane receptors can exist as monomers, as well as dimers. The 
MT1 homodimer forms 3- to 4-fold higher proportion than the MT2 homodimer 
and the MT1/MT2 heterodimer. Nonmammalian vertebrates present a third low-
affinity receptor termed Mel1c, and a proposed mammalian homologous is the 
orphan receptor GPR50 [74, 77–79]. This orphan lost its properties to directly 
interact with melatonin but shows an inhibitory interaction with MT1 receptors by 
forming heterodimers. More recently, other orphans unable to bind melatonin like 
GPR61, GPR62, and GPR135 showed a similar indirect inhibitory interaction with 
MT2 receptors [80]. Other G-protein-coupled receptors like the serotonin receptor 
5HT2c can interact with melatonin membrane receptors [79]. These interesting 
interactions of membrane receptors are not further discussed in this chapter but 
should be considered in future electrophysiological studies with melatonin.
The MT1 and MT2 inhibit adenylate cyclase-protein kinase A-CREB signaling 
in target cells by pertussis toxin-sensitive Gαi, β, and γ and toxin-insensitive Gq, 
β, and γ proteins [74, 79]. The MT1 also increases phosphorylation of mitogen-
activated protein kinase 1/2 (MAPK) and extracellular signal-regulated kinase 1/2 
(ERK), as well as increasing potassium conductance through inwardly rectifying 
(Kir3.x) channels. The later effect on potassium channels could be relevant to heart 
electrophysiology since Kir3.x channels are highly expressed in cardiomyocytes 
and usually coupled to acetylcholine and adenosine membrane receptors [81]. MT2 
melatonin receptor activation inhibits both forskolin-stimulated cAMP production 
and cGMP formation, activates protein kinase C (PKC) in the nervous system, and 
decreases calcium-dependent dopamine release in the retina. Native functional 
MT1/MT2 heterodimers in mouse rod photoreceptors mediate melatonin’s enhance-
ment of scotopic light sensitivity through phospholipase C and PKC pathways [82].
Several compounds interact with MT1 and MT2 receptors, but blocker luzindole 
is the only with proven myocardial electrophysiological effects [83]. Luzindole and 
4P-PDOT competitively block MT1 melatonin receptors at concentrations higher 
than 300 nM, and both are inverse agonists in systems with constitutively active 
MT1 receptors [74, 79].
Melatonin interacts with several enzymes and intracellular proteins. The MT3 
receptors is a quinone reductase 2 with an affinity in the nanomolar ranges [84]. 
This enzyme is possibly involved in the regulation of cellular oxidative status, 
although the exact regulatory action of melatonin remains unclear [84–87]. 
Furthermore, the electrophysiological effects of MT3 have not been reported yet.
Melatonin interacts with intracellular proteins such as calmodulin, calreticulin, 
or tubulin [88]. The low-affinity interaction between melatonin and calmodulin 
antagonizes the binding of Ca2+ and may be involved in its antioxidant action as 
well as other electrophysiological signaling processes [89–96].
Melatonin increases the cytoplasmic levels of the heat shock protein 70 in several 
tissues including the heart [97–102]. Further interaction with this chaperon will be 
described in Section 3 of the chapter.
Melatonin is a ligand for the retinoid-related orphan nuclear hormone receptor 
family (RZR/ROR) [74, 79]. RZR/RORα is expressed in a variety of organs, whereas 
RZRβ is specific for the brain and retina [33]. ROR/RZR has been proposed to work 
in coordination with the plasma membrane receptors MT1/MT2 to regulate gene 
expression. We suggest a potential interaction with Vitamin D receptor (VDR), 
which was elegantly confirmed in recent experiments [97, 103].
1.1.3 Melatonin improves mitochondrial functions
Mitochondria are critical for cellular metabolism and energy production. 
They maintain life but also are gatekeepers of cell death [31, 104]. Mitochondria 
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produce up to 95% of the cellular energy in the form of ATP in aerobic cells 
[105]. Mitochondrial oxidative phosphorylation uses a system of oxidoreductase 
protein complexes (complexes I, II, III, and IV) to transfer electrons during ATP 
production. Deficiencies in the electron transport chain can result in the leakage 
of electrons and generate ROS/RNS [40, 41, 106, 107]. Oxidative stress decreases 
respiratory complex activity, impairs electron transport system, and opens the 
mitochondrial permeability transition pores leading to cell death [104, 106, 108].
Mitochondria are essentials for the protective actions of melatonin [51, 97, 106, 
107, 109–111]. The mechanisms involved include its antioxidant properties and 
the preservation of complex I and III functions, inhibition of the opening of the 
permeability transition pores, and the release of cytochrome c. Petrosillo et al. 
demonstrate that melatonin prevents the opening of the mitochondrial permeabil-
ity transition pores and its deleterious consequences [51, 110, 112, 113]. We recently 
reported that melatonin prevents mitochondrial edema, dilation of the ridges, high 
activity of NADPH oxidase, and apoptosis [97]. Melatonin improves mitofusin-2, 
which preserves the mitochondrial functional network and prevents apoptosis 
[114]. The reduction of mitochondrial damage in the heart could be related to the 
negative regulation of angiotensin II type 1 receptor (AT1) by melatonin [97]. The 
induction of Hsp70 through melatonin is compatible with an additional mechanism 
related to Tom 70, a translocase of the outer mitochondrial membrane [97, 115, 
116]. The interaction of Hsp70 with Tom 70 initiates mitochondrial import pro-
cesses [116]. Tom 70 regulates melatonin-induced cardioprotection by preventing 
mitochondrial deterioration and oxidative stress [97, 115].
Melatonin’s cardioprotection associates with an increase in the number of mito-
chondria and positive regulation of survival genes such as nicotinamide phosphori-
bosyl transferase and nicotinamide adenine dinucleotide-dependent deacetylases, 
called sirtuins [117]. Particularly sirtuin-1 and sirtuin-3 are downstream mediators 
of the cardioprotective actions of melatonin. Sirtuin-1can modulate fatty acid 
oxidation, apoptosis, oxidative stress, and autophagy through deacetylation of 
transduction factors like NF-κB, forkhead box class O, p53, peroxisome proliferator-
activated receptor alpha, thioredoxin-1, and Bcl-xL [117–121]. Sirtuin-3 is a family 
member that is primarily located in the mitochondria and protects against inflam-
mation and diseases related to oxidative stress. Melatonin elevates sirtuin-3, stimu-
lates superoxide dismutase activity, and suppresses mitochondrial oxidative stress 
[31, 117, 122, 123]. Additionally, melatonin protects nuclear and mitochondrial 
DNA [122, 124, 125]. The multiple actions of melatonin provide potent protection 
against mitochondrial-mediated lesions.
1.1.4 Melatonin modulates ion channels
Melatonin exerts its electrophysiological effects by multiple mechanisms. One 
of the ways for melatonin to interact is through the modulation of ion channels. 
Whether we consider its role as a drug or as a biological molecule, it should be taken 
into account how melatonin has been considered an electrophysiological modulator 
for many physiological and clinical conditions such as control of circadian rhythms, 
regulation of arterial blood pressure and heart rate in mammals, sleep processes, 
and antiaging, among others. Its role in the modulation of several ion channels is 
crucial to understand the molecular mechanism underlying the electrophysiological 
properties as an antiarrhythmic.
Melatonin regulates anionic and cationic selective channels by multiple 
pathways, at different doses and time-dependent responses. It is important to 
remember the wide spectrum of action this molecule has. For example, results 
regarding the pathophysiology of lung fibrosis show that volume-regulated anion 
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currents do not respond to acute exposure of cells to melatonin in hypotonic solu-
tions [126]. However, when cells are pre-incubated with melatonin concentrations 
from 1 to 100 μM for 30–60 min, the anionic currents in response to hypotonic-
ity are blunted in a dose-dependent manner. These time- and dose-dependent 
responses could support the electrophysiological effect during regional ischemia 
after 20–30 minutes of melatonin exposure in isolated rat hearts, because during 
ischemia cardiomyocyte swelling activates anionic currents, and melatonin down-
regulation of these currents is a potential explanation [127, 128]. Additionally, 
these MT receptor interactions described in fibroblast deserve further evaluation 
in myocardial tissue.
From the perspective of the interaction between melatonin and its target, it will 
be crucial to increase the knowledge about the allosteric contact between melatonin 
and an ion channel. For example, melatonin blocks the potassium channels (Kv1.3) 
in a reversible manner through the interaction with different binding sites on the 
human peripheral blood T lymphocytes [129]. However, the inhibitory effects 
require high extracellular melatonin in the mM range [129]. Cardiomyocytes do not 
express this specific potassium channel, but a homologous mechanism can exist for 
other channels waiting to be reported.
Most of the information regarding the role and effect of melatonin in the 
organisms has been described in the nervous system. One of the most popular 
is melatonin-related circadian rhythm. In particular, how melatonin influences 
circadian phase and electrical activity thanks to the interaction with Kir3.x channels 
presents them as a therapeutic target for diseases related to circadian disruption 
and melatonin signaling features [130]. In addition, the effects of melatonin in this 
pacemaker of circadian rhythm could be due also to its modulation of inwardly 
rectifying potassium channels (Kir3.1/Kir3.2) via MT1 receptors [131]. Moreover, 
melatonin is also necessary for circadian regulation of sleep. This effect was 
described to be driven by the suppression of GABAergic neurons by melatonin in 
the lateral hypothalamus (crucial function for wakefulness), via interaction with 
MT1 receptor in order to inactivate hyperpolarization-activated cyclic nucleotide-
gated channels [132].
Melatonin is a potential neuroprotective molecule thanks to its interaction in a 
mitochondrial pathway involving the closing of permeability transition pore and 
opening of ATP sensitive potassium channels (KATP) [133]. The opening of KATP 
contributes to melatonin antiseizure effect [134]. The preventive actions on the 
permeability transition pore have been reported in myocardial tissue as well [51, 
112, 113]. However, opening of KATP channels with high concentrations of melato-
nin could be proarrhythmic [135, 136].
Melatonin modulates most of the voltage-activated calcium channel subtypes 
(L, P, Q , N, and R) with different effects [137–141]. Melatonin inhibits voltage-
dependent calcium entry in cultured rat dorsal root ganglia neurons, regulates 
calcium entry into pineal cells, and has dose-dependent inhibitory effects on free 
[Ca2+]i in mouse brain cells [137]. Melatonin has no effect on voltage-activated 
calcium channels in cultured human aortic smooth muscle cells [141]. Melatonin 
accutelly increase L type calcium currents in chick cardiac membranes [140, 141]. 
An early study shows that melatonin downregulates voltage-sensitive calcium chan-
nels in the heart [142]. These results indicate that melatonin may have differnt acute 
and chronic implications for normal cardiac physiology and for the pharmacological 
manipulation of the heart [142].
Melatonin mediates vasodilation of cerebral arteries through the activation of 
large-conductance Ca2+-activated K+ (BKCa) channels via both melatonin receptor-
dependent and melatonin receptor-independent modes, increasing BKCa channel 
current density but not the KV channel current density [143]. Small-conductance 
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Ca2+-activated K (SK) channels are also modulated by the action of melatonin 
[144]. Upregulation of SK channels plays a role in memory loss and indicates that 
melatonin reverses memory deficits in rats by downregulation of SK1, SK2, and SK3 
channels in their hippocampi [144].
Additional information was brought about KCNQ from the aorta and related 
with vascular tone, and KCNH2 in the left ventricle was associated with QT dura-
tion in rats where melatonin was able to prevent the increase in blood pressure and 
change KCNQ and KCNH2 gene expression profiles [145].
Melatonin effects on connexin proteins will be extensively analyzed in the 
second and third sections of the chapters for its proven relationship with both acute 
and chronic antiarrhythmic effects of melatonin.
1.2 Electrophysiology and arrhythmias
The heart pumps blood under a synchronized electrical control. Arrhythmias 
are the electrical problems in the rhythm of the heart. The heartbeats may be faster 
in the case of tachyarrhythmia and slower in bradyarrhythmia.
Fatal arrhythmic events follow a circadian pattern [2]. Arrhythmogenesis 
decreases during nighttime when the melatonin levels increase 30 to 70 folds. Life-
threatening cardiac arrhythmias (ventricular tachycardia, ventricular fibrillation, 
and sudden cardiac death) are more likely to occur in the morning after waking. 
Arrhythmias also increase with age and heart diseases [146–148].
Disturbances in membrane excitability or conduction cause arrhythmias. 
Excitability manifests as action potentials and involves coordinated ion movements 
across the cell membrane through ion channels, exchangers, and ATPases [149]. 
Conduction is the propagation of bioelectrical signal throughout the heart. Action 
potentials automatically originate at the sinoatrial node, spread to the atria, and, 
after a small delay in the atrioventricular node, rapidly and synchronously activate 
the ventricles via the His-Purkinje system. Action potentials propagate from cell 
to cell using low-resistance pathways known as gap junctions. Connexin proteins 
assemble into intercellular channels at gap junctions. Connexin 43 (Cx43) is the most 
abundant connexin in the heart [150]. Gap junctions couple the cells and allow the 
flow of electrical current and small molecules. The largest accumulation of connex-
ins occurs in a specialized structure at the ends of cardiomyocytes called intercalated 
discs. Cardiac propagation is anisotropic, particularly more rapid in the longitudinal 
direction of the cell than in the transverse direction. The lateral borders of the 
myocytes usually show variable amount gap junctions depending on age or disease.
Cardiovascular diseases are the leading cause of death in the world [151]. 
Most deaths occur suddenly [152]. Catastrophic sudden death events motivate 
us to search for causes and possible solutions [153]. This is a great scientific and 
social health challenge. The approaches of recent years have reduced the burden 
of cardiovascular disease, but there is still much to improve [154]. A case occurs 
with arrhythmias. The rhythm disorders motivated emergency interventions, 
especially during the first hour of the manifestation of coronary heart disease. 
Cardiopulmonary resuscitation, ambulances, and cardiodefibrillation were 
response strategies to unexpected events. Unfortunately, they are still unexpected 
due to the limited understanding of the causes at a level that would allow us to pre-
dict, avoid, or control the occurrence of an event [155]. In that sense, the strategies 
that attempt to determine risks grew in order to establish a more efficient direction 
of interventions [156, 157]. Today they allow us to expect more lethal events in 
severely ill people. However, risk factors are still far from being effective and much 
less efficient. The changes that occur in physiology as a result of exposure to differ-
ent risk factors would be one of the explanations [158].
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2. Acute antiarrhythmic mechanisms of melatonin
Melatonin acts at multiple electrophysiological levels due to its receptor-
dependent and receptor-independent mechanisms. In 1998, the seminal work of 
Tan et al. highlighted the antiarrhythmic properties of melatonin [159]. During 
the past two decades, our understanding of the pleiotropic action of melatonin 
increased significantly.
The antiarrhythmic effect of melatonin was first attributed to its notable antiox-
idant properties, mainly because melatonin results were better than those obtained 
with an ascorbic acid at concentration 10–500 times higher [159]. Numerous studies 
confirmed antiarrhythmic protection and related it to its remarkable antioxidant 
properties [160–167].
Our research group corroborated the antiarrhythmic effect of melatonin in 
isolated hearts of female rats, when administered continuously from the stage prior 
to the onset of myocardial ischemia [127]. Notably, the antiarrhythmic protection 
had a dose-dependent response, while the antioxidant capacity was the same for all 
the doses studied. The preventive effect on the shortening of the action potential that 
occurs between the 7th and 10th minute of the ischemia was another dose-dependent 
variable found in our study. This led us to think that the antiarrhythmic mechanism 
could be due to a lower heterogeneity in the repolarization of myocardial tissue that 
diminishes the possibility of reentry circuits being formed and maintained. As previ-
ously mentioned, the time- and dose-dependent responses could be due to melatonin 
inhibitory effect against swell-activated anionic currents [126–128].
We recently showed that melatonin reduces arrhythmias when administered 
during reperfusion, a useful timing for the clinical context of acute coronary syn-
dromes, because most therapies can only start close to the reperfusion period [168]. 
Melatonin showed protective mechanisms when administered to isolated hearts of 
rats fed with fructose and spontaneously hypertensive rats. These animals show 
greater activity of the enzyme NADPH oxidase, which is one of the main systems 
for generating free radicals, and, therefore, higher levels of oxidative stress. The 
antiarrhythmic effect was not affected in the models with greater oxidative stress, 
and in all groups, it was accompanied by a temporary shortening of the duration 
of the action potential during the first 3–5 minutes of reperfusion. This result was 
interpreted as a reduction in the ability to generate early and late postdepolariza-
tions. Self-limited arrhythmic events, such as ventricular extrasystoles, salvos, and 
even non-sustained ventricular tachycardia, occurred in all experimental groups. 
The main difference was that the hearts treated with melatonin did not show sus-
tained forms of arrhythmias, either sustained ventricular tachycardia or ventricular 
fibrillation. These results (potential shortening and absence of sustained arrhyth-
mia) are difficult to reconcile with the mechanisms postulated for reentry circuits.
The same year of our publication of the antiarrhythmic protection of melatonin 
administered in reperfusion, another group published that melatonin protects 
against arrhythmias, by increasing the threshold to electrically induce sustained 
ventricular fibrillation, by increasing the myocardial Cx43 by PKC in hyperten-
sive rats [169]. Melatonin prevented myocardial abnormalities of connexin and 
improved cardiac conduction.
Based in these interesting results, we tested if melatonin could prevent 
hypokalemia-induced ventricular fibrillation by Cx43 preservation [83]. The acute 
administration of melatonin during low potassium perfusion reduced the incidence 
of ventricular fibrillation and improved the recovery of sinus rhythm in those 
hearts that, despite being treated with melatonin, developed sustained fibrilla-
tion. Protection was mediated by the activation of melatonin receptors and by the 
prevention of dephosphorylation and lateralization of Cx43.
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A brief explanation of the electrophysiological changes induced by hypokale-
mia will help to appreciate the relevance as antiarrhythmic. Severe hypokalemia 
induces changes in ventricular repolarization, such as lengthening the QT interval, 
prominent U waves, fusion of T and U waves associated with and increases risk of 
arrhythmic death [83, 170, 171]. Our experimental model confirmed the lengthen-
ing of the QT interval and correlated with an increase in the duration of the action 
potential [83]. Melatonin did not prevent the prolongation of the action potential 
induced by hypokalemia when measured at 90% of repolarization but maintained 
action potential duration at 50% of repolarization and made the membrane poten-
tial more stable, showing less after depolarization. Luzindole blunted both effects 
of melatonin, suggesting the involvement of melatonin receptor activation in the 
preservation of membrane potential.
Hypokalemia decreases NaK-ATPase activity and causes an intracellular Ca2+ 
overload that facilitates the development of delayed postdepolarizations through the 
transient inward currents [172–174]. Delayed postdepolarizations are considered 
triggers of arrhythmias because they can initiate an action potential in isolated cells. 
However, it is unlikely that an extra action potential can be initiated from a single 
cell in the tissue due to a mismatch between the current source from the cell and the 
current sink produced by the surrounding cells [175]. To overcome the source-sink 
mismatch, there must be a reduced sink through intercellular decoupling or an 
increase in the source through the synchronization of delayed postdepolarizations 
between several adjacent cells. Both situations could be assumed based on the 
results of anisotropic conduction studies and immunofluorescence imaging [83].
In fact, hypokalemia induces conduction abnormalities, increased amplitude 
and duration of the P wave, a slight prolongation of the PR interval, atrioventricular 
block, increased QRS duration, and cardiac arrest [173, 176]. We found all these 
electrocardiographic disorders during our experimental model of hypokalemia [83]. 
Melatonin prevented the widening of the QRS and delayed activation of the poten-
tial for epicardial action. The latter could be considered as a substitute for conduc-
tion velocity in complex tissues such as ventricles, assuming unknown routes from 
endocardial activation points that indicate the onset of QRS to epicardial myocytes 
recorded with microelectrodes. These improvements in ventricular conduction were 
related to Cx43 lateralization and dephosphorylation.
The lateralization of connexins has been detected in chronic atrial fibrillation, 
cardiac hypertrophy, heart failure, and after myocardial infarction [21, 177–179]. An 
increase in the fraction of lateral connexins that form functional channels improves 
transverse conduction velocity and contributes to the spread of the arrhythmogenic 
impulse. High side-by-side lateralization can favor conduction blockage due to mis-
matches between the source and the sink [175, 180]. A unidirectional block can lead 
to reentry circles that result in tachycardia or ventricular fibrillation [181]. Therefore, 
the acute lateralization induced by hypokalemia is an important arrhythmogenic 
factor [83]. It is noteworthy that melatonin prevented acute lateralization of Cx43.
Connexin 43 phosphorylation could lead to better coupling or uncoupling 
depending on the target amino acid, but dephosphorylation is clearly associated 
with uncoupling [21, 177, 182]. It is not yet known whether the dephosphorylation of 
Cx43 during low potassium is the result of increased phosphatase activity and/or an 
increase in phosphokinase or what are the intracellular mechanisms that prevented 
dephosphorylation when treated with melatonin. Dramatic reductions in intercellular 
communication due to the loss of phosphorylated Cx43 and the accumulation of non-
phosphorylated Cx43 were previously reported in other experimental models [177].
Our results could be relevant mainly in those situations in which acute hypo-
kalemia can be anticipated as in dialysis [183, 184]. Both QT interval and the QT 
dispersion increase after dialysis. We propose that melatonin could make the heart 
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more resistant to arrhythmic events triggered by rapid changes in plasma electro-
lyte concentrations, regardless of a lack of effects on the ECG. In addition, those 
dialysis patients also suffer from disorders in the circadian rhythms and low levels 
of melatonin [185]. However, clinical translations of our results should be done with 
caution, mainly because we use a high dose of melatonin administered directly to 
the heart. Based on melatonin’s pharmacokinetics in humans, to achieve a similar 
concentration in plasma to the one tested ex vivo, a dose 10 times higher the highest 
intravenous dose tested until now should be administered [186, 187].
Melatonin has a remarkable antiarrhythmic activity that is carried out based 
on actions dependent on and independent of receptor activation. To summarize 
we propose that the antiarrhythmic effect of melatonin is mediated by receptor 
activation beyond its outstanding antioxidant actions (Figure 1). The shortening 
of the action potential could be associated with the activation of MT1 melatonin 
receptors, since they can regulate specific ion channels such as Kir3.1 channel. MT1 
and MT2 receptors could indirectly modulate other electrophysiological effects 
through intracellular signaling such as decreased cyclic adenosine monophosphate, 
increased phospholipase C, and PKC activation.
3. Chronic antiarrhythmic mechanisms of melatonin
Endogenous melatonin would be an intrinsically protective factor with thera-
peutic potential [188, 189]. Melatonin is a promising treatment for cardiovascular 
diseases such as myocardial ischemia/reperfusion injury, hypertension, and heart 
failure. It has been shown that melatonin levels were reduced in patients with acute 
myocardial infarction and in patients undergoing primary coronary angioplasty 
[190]. These findings suggest that melatonin could play an important role in 
preventing ischemia/reperfusion heart injury. Indeed, reperfusion arrhythmias 
increase in pinealectomized animals, suggesting a protective role of endogenous 
physiological melatonin levels [163, 189].
Chronic melatonin supplementation, either in physiological or pharmacologi-
cal ranges, protects against arrhythmias [8, 21, 97, 163, 169, 189, 191, 192]. Beyond 
the reported antioxidant properties of melatonin, it reduces severe ventricular 
Figure 1. 
Acute antiarrhythmic mechanisms of melatonin. The red arrows indicate stimulation, and the interrupted blue 
lines indicate blockage.
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arrhythmias by antifibrotic mechanisms, electrical remodeling, direct mitochon-
drial protection, myocardial Cx43 preservation via PKC signaling, and vitamin 
D-HSP70/AT1 counterbalance (Figure 2). Its cardioprotective properties persist in 
relevant cardiovascular risk factor models like hypertensive, obese, and nephro-
pathic rats. The latter is interesting because most of the therapeutic interventions 
postulated so far fail to be reproduced under risk factor conditions.
A preventive approach would be of great value in the face of unpredictable acute 
arrhythmic events, especially if the intervention manages to avoid the most severe 
and potentially lethal arrhythmias such as ventricular tachycardia and fibrillation. 
Numerous efforts have been made in that direction. In the last quarter of the twentieth 
century, several antiarrhythmic drugs were tried, but most of them showed a proar-
rhythmogenic profile or failed to reduce mortality [193–196]. A time of great progress 
was appreciated with the introduction of implantable cardiodefibrillators. However, 
surgical intervention and high cost limit its population efficiency. A strategy to improve 
the availability of preventive interventions is to select potential beneficiaries based 
on their risk of serious events. This would compensate for potential side effects and 
optimize the investment of resources. Other strategies, such as vaccines, are based on 
achieving the greatest possible scope with the least number of interventions that attenu-
ate the severity of diseases. In the case of arrhythmias, we still have no clear “antiar-
rhythmic vaccine.” Therefore, risk-oriented strategies would be an acceptable approach.
From a preventive point of view, the pleiotropic protection mechanisms of 
melatonin could effectively limit the arrhythmic complications associated with 
hypertension [21, 169]. Arterial hypertension causes vascular deterioration, over-
loads the heart, and predisposes to a greater number of arrhythmic events. More 
than five decades ago, it was reported that surgical removal of the pineal gland, 
a procedure that essentially eliminates circulating levels of melatonin, was followed 
by a slow but persistent increase in blood pressure in rats [197]. This finding has 
been confirmed in several subsequent studies [11]. In addition, daily treatment of 
pinealectomized rats with melatonin attenuated the elevation in blood pressure 
Figure 2. 
Antiarrhythmic mechanisms of chronic melatonin administration. Extracellular lines represent reduced fibrosis 
after melatonin treatment. The red arrows indicate stimulation and blue ones show blockage. The green arrow 
marks direct mitochondrial protection.
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that accompanies pinealectomy [198, 199]. Potentially related to these experimental 
findings are those observational studies in humans that document an age-related 
gradual increase in blood pressure [7]. Of special interest is that the ability of the 
pineal gland to produce melatonin is compromised during aging so that the levels of 
melatonin in the blood at night gradually decrease [28, 30, 110]. An implication of 
these findings is that the loss of melatonin during aging can contribute to gradual 
hypertension and arrhythmias.
The structural remodeling of the myocardium that follows hypertension (mainly 
cardiomyocyte hypertrophy and fibrosis) is accompanied by changes in the expres-
sion, distribution and function of the ionic channels of the cell membrane and the 
intercellular channels constituted by Cx43 [21, 191, 200]. Remodeling predisposes 
to life-threatening ventricular tachycardia and ventricular fibrillation by early or 
late postdepolarization and reentry. Melatonin prevents changes in ventricular 
redistribution of Cx43 and reduces arrhythmia inducibility [8, 21, 147, 191].
Another chronodisruptor that increases arrhythmic risk are kidney diseases. 
Chronic kidney diseases (CKD) alter the nocturnal secretion of melatonin [185, 
201]. Melatonin levels correlate negatively with the intrarenal activity of renin-
angiotensin II-aldosterone system (RAAS) [202]. Melatonin improves intrarenal 
RAAS in the 5/6 nephrectomy rat model and reduces blood pressure, oxidative 
stress, and interstitial fibrosis in the remaining kidneys [203].
Renal diseases cause cardiovascular and electrolytic remodeling that increases 
the risk of arrhythmias [204–206]. Cardiovascular events occur more frequently 
in patients with chronic kidney disease. Ventricular arrhythmias are particularly 
prevalent among patients with CKD, even when those patients do not suffer from 
any electrolyte imbalance [207]. The risk of mortality also increases in patients with 
CKD who suffer from an acute coronary syndrome [208]. We demonstrated that 
unilateral ureteral obstruction caused a cardiac remodeling that was accompanied 
by an increase in reperfusion arrhythmias [209].
The electrophysiological properties of chronic melatonin deserve attention, due 
to their relevance for cardiorenal situations with high arrhythmic risk and lack of 
treatments. We recently confirmed the antifibrotic, antiapoptotic, and antioxidant 
effects of melatonin and linked them to an HSP 70-VDR/AT1 counterbalance which 
prevents kidney damage and arrhythmogenic remodeling of the heart [97].
In renal and myocardial tissue, melatonin increased HSP 70 and VDR and 
decreased AT1 and fibrosis. Melatonin increases HSP 70 and protects the liver of 
rats exposed to toluene from cytotoxicity induced by oxidative stress [100]. HSP 70 
regulates antioxidant responses to cellular oxidative stress and reduces NADPH oxi-
dase activity and expression [210]. We demonstrated a myocardial increase in HSP 
70 in rats treated with melatonin. HSP 70 induces VDR and facilitates intracellular 
localization of active vitamin D metabolites and transactive VDRs [209, 211, 212]. 
Nuclear melatonin receptors, as members of retinoid-related orphan receptors, 
may interact and prevent degradation of VDR [97, 103]. Expression of myocardial 
VDR links chronic kidney disease with cardiovascular disease due to the reduction 
in VDR that amplifies the effects of angiotensin [212]. Melatonin decreases renal 
and myocardial overexpression of AT1 [97]. It is well documented that the AT1 
pathway leads to myocardial fibrosis during CKD [97]. As previously suggested, 
the low expression of AT1 through VDR induction could be a consequence of HSP 
70-mediated cellular protection [213]. Angiotensin II exerts a tonic modulation of 
melatonin synthesis by influencing the activity of tryptophan hydroxylase through 
AT1 supporting the postulated feedback (or reciprocal regulation) between AT1 
and melatonin [97, 202].
Additionally, the mitochondrial dynamics relates to the RAAS. We show that 
melatonin prevents mitochondrial edema, high activity of NADPH oxidase, and 
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apoptosis. In this sense, the reduction of mitochondrial damage melatonin could be 
related to the negative regulation of AT1. The induction of HSP 70 through melato-
nin is compatible with an additional mechanism related to Tom 70. Furthermore, 
Tom 70 regulates melatonin-induced protection against myocardial infarction 
[115, 116]. All these data allow us to assume that the induction of HSP 70 by melato-
nin and the reduction of AT1 are critical components of the cellular stress response.
We attribute the higher vulnerability to ventricular fibrillation during reperfu-
sion in the kidney disease rat model to the prooxidative and profibrotic changes that 
accompanied the increase in AT1 and the decrease in HSP 70 [97, 209]. Myocardial 
oxidative stress—particularly in the mitochondria—and fibrosis are well-known 
proarrhythmic substrates [55, 71]. Free radicals act as triggers for the beginning of 
arrhythmic events. The persistence of high-frequency rhythms requires reentry 
circuits [214]. Altered conduction and shortening of the action potential contribute 
to the complex reentry mechanisms involved in ventricular fibrillation.
Melatonin protection against myocardial remodeling induced by kidney disease 
is one of the factors that protect against ventricular fibrillation. Chronic melatonin 
prolongs the action potential duration and hyperpolarizes the cardiomyocytes. These 
changes are the first report of myocardial action potential modifications by chronic 
administration of melatonin. Opening of Kir3.x channels by melatonin receptor 
activation could explain hyperpolarization [131]. The action potential lengthening 
is harder to explain because melatonin activates currents involved in the action 
potential repolarization and the only inhibitory effect of melatonin against outward 
potassium currents was described in neurons [90, 129, 130, 215–217]. As previously 
mentioned, the downregulation of volume-activated anionic currents can explain 
attenuated response to action potential shortening induced by ischemia [126].
A synthesis of the mechanisms of protection of chronic treatment of melatonin 
cardiovascular complications is outlined in Figure 2. We focus our attention on 
the preventive effects of melatonin against the alteration of Cx43, mitochondrial 
oxidant capacity, and membrane potentials. In addition, modulation of the AT1 and 
VDR receptors related to the increase of HSP 70 contributes to the cardioprotective 
effects of melatonin.
4. Conclusions
Melatonin is the rhythmic protector of healthy heart rhythm and a promising 
preventive agent against ventricular fibrillation, the most lethal and disorganized 
heart rhythm. Pleotropic effects of melatonin make it an exceptional acute and 
chronic antiarrhythmic.
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